HK1142496A1 - Therapeutic pyrazoloquinoline urea derivatives - Google Patents

Therapeutic pyrazoloquinoline urea derivatives

Info

Publication number
HK1142496A1
HK1142496A1 HK10109113.1A HK10109113A HK1142496A1 HK 1142496 A1 HK1142496 A1 HK 1142496A1 HK 10109113 A HK10109113 A HK 10109113A HK 1142496 A1 HK1142496 A1 HK 1142496A1
Authority
HK
Hong Kong
Prior art keywords
urea derivatives
pyrazoloquinoline
therapeutic
therapeutic pyrazoloquinoline
urea
Prior art date
Application number
HK10109113.1A
Other languages
English (en)
Inventor
Alan P Kaplan
Varsha Gupta
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of HK1142496A1 publication Critical patent/HK1142496A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10109113.1A 2007-06-08 2010-09-24 Therapeutic pyrazoloquinoline urea derivatives HK1142496A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94299207P 2007-06-08 2007-06-08
PCT/US2008/066205 WO2008154442A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazoloquinoline urea derivatives

Publications (1)

Publication Number Publication Date
HK1142496A1 true HK1142496A1 (en) 2010-12-10

Family

ID=40096439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10109113.1A HK1142496A1 (en) 2007-06-08 2010-09-24 Therapeutic pyrazoloquinoline urea derivatives

Country Status (13)

Country Link
US (2) US7863266B2 (xx)
EP (1) EP2164328B8 (xx)
JP (1) JP2010529144A (xx)
KR (1) KR20100038189A (xx)
CN (1) CN101686682A (xx)
AU (1) AU2008261888A1 (xx)
BR (1) BRPI0812347A2 (xx)
CA (1) CA2688405A1 (xx)
ES (1) ES2433566T3 (xx)
HK (1) HK1142496A1 (xx)
IL (1) IL202286A0 (xx)
MX (1) MX2009013205A (xx)
WO (1) WO2008154442A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
JP2010529144A (ja) * 2007-06-08 2010-08-26 ヘリコン・セラピューティクス・インコーポレーテッド 治療用ピラゾロキノリン尿素誘導体
WO2011049731A1 (en) * 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN106187887B (zh) * 2016-07-01 2018-08-14 上海工程技术大学 4-羟基喹啉-3-甲酸的制备方法
UA126119C2 (uk) 2016-11-11 2022-08-17 Баєр Енімал Хелс Гмбх Протигельмінтні похідні хінолін-3-карбоксаміду

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1357A (en) * 1979-06-21 1987-08-07 Ciba Geigy Ag Pyrazolo-quinolines, processes for their production, pharmaceutical compositions containing them and their therapeutical use
DE3204126A1 (de) 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
US4814450A (en) * 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
WO1992022552A1 (en) * 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
US5334595A (en) 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
US5792766A (en) * 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
GB9716344D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
GB9716347D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
GB9716345D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP3953424B2 (ja) * 2001-02-21 2007-08-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗うつ薬としてのイソキサゾリン誘導体
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
ATE425164T1 (de) * 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
WO2005028474A2 (en) * 2003-05-29 2005-03-31 Millennium Pharmaceuticals, Inc. Pyrazoloquinoline derivatives as chk-1 inhibitors
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20070078083A1 (en) 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION
EP2597087B1 (en) * 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
WO2008154447A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives
JP2010529144A (ja) * 2007-06-08 2010-08-26 ヘリコン・セラピューティクス・インコーポレーテッド 治療用ピラゾロキノリン尿素誘導体
MX2009013202A (es) * 2007-06-08 2010-04-09 Helicon Therapeutics Inc Derivados terapeuticos de pirazoloquinolina.

Also Published As

Publication number Publication date
BRPI0812347A2 (pt) 2016-08-02
CN101686682A (zh) 2010-03-31
IL202286A0 (en) 2010-06-16
ES2433566T3 (es) 2013-12-11
EP2164328B8 (en) 2013-09-11
WO2008154442A1 (en) 2008-12-18
JP2010529144A (ja) 2010-08-26
US20110071140A1 (en) 2011-03-24
EP2164328A1 (en) 2010-03-24
MX2009013205A (es) 2010-04-09
CA2688405A1 (en) 2008-12-18
KR20100038189A (ko) 2010-04-13
AU2008261888A1 (en) 2008-12-18
US20080306048A1 (en) 2008-12-11
EP2164328B1 (en) 2013-08-07
US7863266B2 (en) 2011-01-04
EP2164328A4 (en) 2010-06-23
US8343957B2 (en) 2013-01-01

Similar Documents

Publication Publication Date Title
EP2117311A4 (en) THERAPEUTICS
IL196559A0 (en) Combination therapy
HRP20130041T8 (xx) Terapijska sredstva
IL199992A0 (en) Combination therapy
IL196556A0 (en) Combination therapy
GB0723747D0 (en) Therapeutic agents
HK1142496A1 (en) Therapeutic pyrazoloquinoline urea derivatives
EP2054061A4 (en) COMBINATION THERAPY
EP2004154A4 (en) THERAPEUTIC BELT
GB0719518D0 (en) Therapy
HK1142774A1 (en) Therapeutic pyrazolonaphthyridine derivatives
ZA200902203B (en) Combination therapy
EP2211863A4 (en) COMBINATION THERAPY
GB0700284D0 (en) Combination therapy
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
GB0808690D0 (en) Therapeutic use
GB0723748D0 (en) Therapeutic agents
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0703963D0 (en) Therapy
GB0705917D0 (en) Therapy
GB0723749D0 (en) Therapeutic agents
GB0725030D0 (en) Therapeutic agents
GB0723751D0 (en) Therapeutic agents
GB0709495D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170606